Home Glycart Biotechnology AG

Glycart Biotechnology AG

acquired
Series A
Developer of Antibody-Based Products
Basic
Enterprise Profile

Basic Information

Glycart Biotechnology AG researches, develops, and commercializes novel potent antibody products for the treatment of unmet clinical needs, such as cancer.
Glycart Biotechnology AG
Zurich,Zurich,Switzerland
15~50 people
January 01, 2000
--

Enterprise Profile

Technology
Biotechnology
Concept
Tumor
Application Scenarios
Drug Concepts